A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease.

Trial Profile

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 29 Apr 2016 Results published in a Acadia Pharmaceuticals media release.
    • 29 Apr 2016 According to ACADIA Pharmaceuticals media release, the US FDA has approved pimavanserin (NUPLAZID) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval was based on the results from this and other supportive trials.
    • 02 Nov 2015 Positive results were published as per ACADIA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top